MetaCap

Drugs Made In America Acquisition II Quarterly Balance Sheet

NASDAQ: DMIIFinanceBlank ChecksUSD

10.190.00 (0.00%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Drugs Made In America Acquisition II financial position

As of Jun 30, 2026, Drugs Made In America Acquisition II reported total assets of $514.1 million against total liabilities of $18.1 million. Shareholders' equity was negative at -$17.9 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $174,974 in cash and equivalents against $450,000 of debt, a net debt position of $275,026.

The current ratio (current assets divided by current liabilities) was 0.34, meaning short-term obligations exceed short-term assets.

Summary generated from market data by MetaCap's automated system. Methodology

Drugs Made In America Acquisition II balance sheet (quarterly)

Drugs Made In America Acquisition II quarterly balance sheet
Quarter (USD)Q2 20262026-06-30Q1 20262026-03-31Q4 20252025-12-31Q3 20252025-09-30Q2 20252025-06-30Q1 20252025-03-31
Cash & Equivalents174.97K347.72K223315.09K4.39K6.99K
Total Current Assets217.82K351.76K26.04K896.36K——
Total Assets514.10M509.73M504.96M501.01M——
Accounts Payable12.25K49.17K99.36K4.59K——
Short-Term Debt450.00K450.00K————
Total Current Liabilities644.57K666.28K300.86K677.35K——
Total Liabilities18.14M18.17M17.80M18.18M——
Shareholders' Equity-17.93M-17.81M-17.77M-17.28M-214.12K-176.05K
Retained Earnings-17.93M-17.82M-17.78M-17.28M——
Total Debt450.00K450.00K————
Net Cash (Debt)-275.03K-102.28K223315.09K4.39K6.99K
Shares Outstanding13.70M13.70M13.70M15.57M——

This table shows 6 quarterly periods of Drugs Made In America Acquisition II's balance sheet, from Q2 2026 back to Q1 2025, across 12 line items including cash & equivalents, total current assets, total assets. Values in USD; B = billions, M = millions. Fiscal periods follow DMII's reporting calendar. What is a balance sheet?

More financial data